CDT Equity Inc.
CDTHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeCDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company carries a $8.4M market cap, placing it firmly in the micro-cap category. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Market Cap
$8.4M
Beta
1.45
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-3050.69
EPS (Fwd)
—
ROE
-69.7%
ROA
-23.4%
Cash
$747,000
Total Debt
$1.2M
Free CF
$19.6M
52W Change
-100.0%
Annual Financials
Cash vs Debt
Where CDT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CDT finished 86.66% below its 150-day moving average ($6.82) and 94.01% below its 200-day moving average ($15.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDT overbought or oversold?
At the September 3, 2026 close, CDT's RSI(14) was 7.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $747K in cash, though total debt stands at $1.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $19.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -69.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
As with any equity investment, CDT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing CDT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.